|Partial Close, 5/2009 ||$2.65M|
|Series B, 8/2010 |
|Series B, 11/2012 ||$13M|
|Private Equity, 11/2012 ||$9.11M|
Metamark Genetics, Inc is a life science company dedicated to the development of prognostic and predictive diagnostic tests that will enable personalized treatment planning for cancer patients, improved outcomes, and reduced healthcare costs.
Metamark was founded in November, 2007 to transform cancer diagnosis and treatment by developing pioneering diagnostic products based on its Prognosis Determinantsâ„¢ Platform. Prognosis Determinantsâ„¢ are functionally validated genetic elements at the core of cancer progression across many major cancer types. Based on pioneering research in melanoma by Dr. Lynda Chin at the Dana-Farber Cancer Institute and Harvard Medical School, the Prognosis Determinantsâ„¢ were first discovered as functionally active drivers of metastasis that confer poor outcome. Prognosis Determinantsâ„¢ have been shown to be relevant to a broad spectrum of different tumors and can stratify patients according to their overall and metastasis-free survival.